Brief: Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits Of Zephyr Valve For Patients With Severe Copd/Emphysema
27/07/2021 15:33
July 27 (Reuters) - Pulmonx Corp LUNG.O :
* PULMONX ANNOUNCES LONG-TERM FOLLOW-UP DATA CONFIRMING
SIGNIFICANT BENEFITS OF ZEPHYR VALVE FOR PATIENTS WITH SEVERE
COPD/EMPHYSEMA
Source text for Eikon: ID:nBw3r3Km5a
Further company coverage: LUNG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulmonx
See all newsBrief: Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pulmonx Corp reports results for the quarter ended June 30 - Earnings Summary
Pulmonx Corp Q2 revenue falls, but beats estimates
Brief: Pulmonx Q2 EPS USD -0.24
Pulmonx Corp expected to post a loss of 28 cents a share - Earnings Preview